Relmada Therapeutics, Inc.

Najib Babul

The present invention is directed to therapeutic pharmaceutical compositions of 1-Methyl-2', 6&#x2032;-pipecoloxylidide or it pharmaceutically acceptable salts for application to the skin and the use thereof.

Dermal pharmaceutical compositions of 1-methyl-2',6&#x2032;-pipecoloxylidide and method of use

The present invention is directed to oral, therapeutically effective modified release pharmaceutical compositions of (&#x2212;)-17-(cyclobutylmethyl)morphinan-3,14-diol and it pharmaceutically acceptable salts and the use thereof, including delayed onset and extended release dosage forms. The present invention is also directed at modified release dosage forms of oral (&#x2212;)-17-(cyclobutylmethyl)morphinan-3,14-dial which provide robust efficacy and reduced potential for abuse and misuse.

Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol

The present invention is directed to oral, therapeutically effective modified release pharmaceutical compositions of (&#x2212;)-17-(cyclobutylmethyl)morphinan-3,14-diol and it pharmaceutically acceptable salts and the use thereof, including delayed onset and extended release dosage forms. The present invention is also directed at modified release dosage forms of oral (&#x2212;)-17-(cyclobutylmethyl)morphinan-3,14-diol which provide robust efficacy and reduced potential for abuse and misuse.

Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol

The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioid agonists, extended release pharmaceutical compositions of opioid agonists and extended release abuse resistant pharmaceutical compositions of opioid agonists and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.

Multimodal abuse resistant and extended release opioid formulations

The present invention is directed at methods for preventing or minimizing the intensity of the serotonin syndrome in humans and lower animals which comprises administering proserotonergic agents and serotonin surge protectors. The present invention is also directed to pharmaceutical compositions comprising proserotonergic agents and serotonin surge protectors useful for carrying out the method of the present invention.

Growing community of inventors

Blue Bell, PA, United States of America

Najib Babul